International Orthopaedics

, Volume 36, Issue 4, pp 703–709

Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty

Authors

  • Melita Buljan
    • Department of Orthopaedic Surgery, Clinical Hospital Centre ZagrebSchool of Medicine, University of Zagreb
  • Damir Nemet
    • Department of Internal Medicine, Division of HematologyUniversity Hospital Centre Zagreb
  • Branka Golubic-Cepulic
    • Department of Clinical TransfusiologyUniversity Hospital Centre Zagreb
    • Department of Orthopaedic Surgery, Clinical Hospital Centre ZagrebSchool of Medicine, University of Zagreb
  • Branko Tripkovic
    • Department of Orthopaedic Surgery, Clinical Hospital Centre ZagrebSchool of Medicine, University of Zagreb
  • Domagoj Delimar
    • Department of Orthopaedic Surgery, Clinical Hospital Centre ZagrebSchool of Medicine, University of Zagreb
Original Paper

DOI: 10.1007/s00264-011-1367-7

Cite this article as:
Buljan, M., Nemet, D., Golubic-Cepulic, B. et al. International Orthopaedics (SICOT) (2012) 36: 703. doi:10.1007/s00264-011-1367-7

Abstract

Purpose

Our aim was to evaluate the effectiveness of two different dosing regimens of human recombinant erythropoietin (rHu-EPO) for preoperative autologous blood collection in patients undergoing total hip arthroplasty (THA).

Methods

Prospective randomised trials in which erythropoietin 15,000 IU was administered intravenously twice a week or 30,000 IU once a week (total 90,000 IU) combined with ferrous II sulphate (Ferro-Gradumet 2) orally and compared with Ferro-Gradumet 2 alone.

Results

Although different dosing regimens of rHu-EPO administration during preoperative autologous blood donation have similar effects on the collection of two units of autologous blood, preoperative haemoglobin level and perioperative allogenic blood transfusion, a once weekly dose regimen of rHu-EPO was more convenient (although not statistically significantly) for patients.

Conclusion

We recommend the more practical and comfortable but yet highly effective therapeutic regimen with a single weekly intravenous administration of rHu-EPO for patients scheduled for THA.

Copyright information

© Springer-Verlag 2011